A novel therapeutic approach has been suggested for advanced-stage cutaneous melanoma, whereby a BRAF mutation at codon 600 has been identified, leading to a novel approach for drug development in the advanced setting (35). The gene discussed is BRAF; the disease is cutaneous melanoma.